Uncategorized
Tyrogenex initiates phase 2 study of X-82 for wet AMD
Tyrogenex has initiated a phase 2 study of X-82 for the treatment of wet age-related macular degeneration, according to a press release.The treatment is a dual inhibitor of VEGF and PDGF that is administered orally.